NCT07508904 Exercises' Effect on Muscle Strength, Aerobic Capacity and Respiratory Functions in Cystic Fibrosis
| NCT ID | NCT07508904 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Riphah International University |
| Condition | Cystic Fibrosis (CF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 22 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 22 participants in total. It began in 2025-12-01 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research aims to evaluate the effects of upper and lower limb exercises on muscle strength and pulmonary function in children diagnosed with CF. While aerobic training is a known component of CF management, resistance training focused on specific limb groups has gained attention for its additional benefits. Upper limb exercises may aid respiratory muscle endurance and thoracic mobility, enhancing pulmonary mechanics. In contrast, lower limb exercises (such as cycling or squats) are associated with improved oxygen consumption (VO₂ peak), enhanced mobility, and greater lower body strength. This randomized clinical trial will be conducted using a non-probability convenience sampling technique. The study will take place at the pediatric cystic fibrosis centers of Gulab Devi Chest Hospital and The Children's Hospital, Lahore. The targeted population includes children aged 6 to 18 years who have been diagnosed with cystic fibrosis and referred to the physiotherapy department. The study duration will be ten months following the approval of the synopsis. Eligible participants will be children aged between 6 and 18 years, clinically diagnosed with cystic fibrosis, currently stable with no history of hospitalization or significant lung infection in the past month. They should be physically able to participate in exercise and capable of following instructions, with informed consent obtained from their parents or guardians. Children will be excluded if they suffer from other severe lung diseases, cardiovascular or orthopedic conditions that restrict exercise, recent surgery or hospitalization within the last month, or if they are unable to understand instructions. Those dependent on oxygen therapy or ventilator support at all times will also be excluded. The primary outcome measures will include lung function assessed by spirometry (FVC, FEV1), sputum production recorded through a sputum diary, and aerobic capacity measured by the Incremental Shuttle Walk Test (ISWT). Muscle strength will be evaluated for both upper and lower limbs, using a handheld dynamometer for the upper limbs and the Sit-to-Stand Test for the lower limb
Eligibility Criteria
Inclusion Criteria: * Children aged 6-18 years * Diagnosed with cystic fibrosis * Clinically stable * Able to perform exercise * Parental/guardian consent provided Exclusion Criteria: * Other severe pulmonary diseases * Cardiovascular or orthopedic limitations * Surgery or hospitalization within last 1 month * Inability to follow instructions * Oxygen-dependent or ventilator-dependent patients
Contact & Investigator
Danish Hassan, PhD
PRINCIPAL INVESTIGATOR
Riphah International University
Frequently Asked Questions
Who can join the NCT07508904 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 18 Years, studying Cystic Fibrosis (CF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07508904 currently recruiting?
Yes, NCT07508904 is actively recruiting participants. Contact the research team at danish.hassan009@gmail.com for enrollment information.
Where is the NCT07508904 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT07508904 clinical trial?
NCT07508904 is sponsored by Riphah International University. The principal investigator is Danish Hassan, PhD at Riphah International University. The trial plans to enroll 22 participants.